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OBJECTIVE—The requirement of systemic immunosuppression
after islet transplantation is of signiﬁcant concern and a major draw-
back to clinical islet transplantation. Here, we introduce a novel
composite three-dimensional islet graft equipped with a local immuno-
suppressive system that prevents islet allograft rejection without
systemic antirejection agents. In this composite graft, expression of
indoleamine 2,3 dioxygenase (IDO), a tryptophan-degrading enzyme, in
syngeneic ﬁbroblasts provides a low-tryptophan microenvironment
within which T-cells cannot proliferate and inﬁltrate islets.
RESEARCH DESIGN AND METHODS—Composite three-
dimensional islet grafts were engineered by embedding allogeneic
mouse islets and adenoviral-transduced IDO–expressing syngeneic
ﬁbroblasts within collagen gel matrix. These grafts were then trans-
planted into renal subcapsular space of streptozotocin diabetic
immunocompetent mice. The viability, function, and criteria for graft
take were then determined in the graft recipient mice.
RESULTS—IDO-expressing grafts survived signiﬁcantly longer
than controls (41.2  1.64 vs. 12.9  0.73 days; P  0.001) without
administration of systemic immunesuppressive agents. Local ex-
pression of IDO suppressed effector T-cells at the graft site, induced
a Th2 immune response shift, generated an anti-inﬂammatory
cytokine proﬁle, delayed alloantibody production, and increased
number of regulatory T-cells in draining lymph nodes, which
resulted in antigen-speciﬁc impairment of T-cell priming.
CONCLUSIONS—Local IDO expression prevents cellular and
humoral alloimmune responses against islets and signiﬁcantly
prolongs islet allograft survival without systemic antirejection
treatments. This promising ﬁnding proves the potent local immu-
nosuppressive activity of IDO in islet allografts and sets the stage
for development of a long-lasting nonrejectable islet allograft
using stable IDO induction in bystander ﬁbroblasts. Diabetes
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ndocrine replacement therapy by islet trans-
plantation represents a feasible and attractive
alternative therapeutic approach for treating
type 1 diabetes (1,2). Despite improvement of
allogeneic islet engraftment using systemic immunosup-
pression, islet transplantation is still limited by high rates
of rejection. Furthermore, some immunosuppressive
agents are prodiabetogenic and associated with adverse
side effects (3–6). Finding more efﬁcient and less harmful
strategies to protect islet graft is therefore required for
improving islet transplantation outcome.
Localized expression of immunoregulatory factors using
gene transfer to graft is a feasible method to provide an
immunoprivileged microenvironment and consequently
improves graft survival. Such an on-site delivery system
results in more potent local immunosuppression with less
systemic side effects (7–9).
IDO is a cytosolic enzyme that catalyzes essential amino
acid L-tryptophan to kynurenine (10) and has profound
effects on T-cell proliferation, differentiation, effector func-
tions, and viability (11). Both the reduction in local
tryptophan concentration and the production of immuno-
modulatory tryptophan metabolites contribute to immuno-
suppressive effects of IDO (12,13). Broad evidence
implicates IDO and the tryptophan catabolic pathway in
generation of immune tolerance to antigens in tissue
microenvironments. In particular, the role of IDO in fetal
tolerance in mammalian pregnancy (14,15), immunologic
tolerance to tumors (16,17), and self-tolerance has been
documented (18,19). The unique immunoregulatory func-
tion of IDO substantiates the application of this enzyme
as a strategy to suppress alloimmune responses in
transplantation.
Our research group has shown that overexpression of
IDO in ﬁbroblasts suppresses immune response and im-
proves outcome of skin grafts (20–25) and that bystander
IDO-expressing ﬁbroblasts suppress immune response to
allogeneic mouse islets in vitro (26). Furthermore, in a
recent study we showed that mouse islets and ﬁbroblasts
are selectively resistant to IDO-mediated activation of
nutrient deﬁciency stress (27). Here, we engineered a
three-dimensional composite islet allograft equipped with
IDO-expressing ﬁbroblasts and examined whether local
expression of IDO, conferred by adenoviral-mediated gene
transfer to bystander syngeniec ﬁbroblasts, prevents the
rejection of islet allograft. Our approach here is novel
compared with other studies that examined the suppres-
sive effect of IDO in islet transplantation (28,29) because
1) bystander syngeneic ﬁbroblasts were used as the target
of gene transfer instead of islets to avoid deleterious
effects of adenovirus infection on islets (30–32), 2) islets
were embedded within an extracellular matrix that by
itself improves islet function and viability (33,34), and 3)
cotransplanted ﬁbroblasts are more than just a source of
IDO and can enhance islet physiological competence
(35,36).
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Mouse islet isolation and preparation of three-dimensional islet-ﬁbro-
blast composite grafts. Islets were isolated from 6- to 8-week-old male
BALB/c mice (The Jackson Laboratories, Bar Harbor, ME), and mouse dermal
ﬁbroblasts were explanted from B6 mice skin and transduced with a recom-
binant adenoviral vector carrying human IDO cDNA as previously described
(26). Control ﬁbroblasts were infected with a mock vector or left untreated.
Fibroblast-populated collagen gel (FPCG) matrices were prepared as de-
scribed by Sarkhosh et al. (23) using IDO-expressing or control ﬁbroblasts.
Mouse islets were added to FPCG before solidiﬁcation in 24-well plates. Care
and maintenance of all animals were in accordance with the principals of
laboratory animal care and the guidelines of the institutional Animal Policy
and Welfare Committee.
Transplantation of islet-ﬁbroblast composite grafts and evaluation of
graft function. Recipient C57BL/6 (B6) mice were rendered diabetic by a
single intraperitoneal injection of 200 mg/kg streptozotocin (Sigma), and
diabetes was deﬁned as a minimum of two consecutive blood glucose
measurements 20 mmol/l. Islet plus IDO-expressing or control ﬁbroblast
composite grafts (500 islets) were transplanted under the left kidney capsule
of isoﬂurane-anesthetized diabetic mice. After transplantation, blood glucose
levels were measured using an Accu-Chek Compact Plus blood glucose
monitoring system, and grafts were deemed functioning when blood
glucose levels decreased to 10 mmol/l. Intraperitoneal glucose tolerance
tests (IPGTT) were performed as previously described (27) 2 and 4 weeks
after transplantation. All animals were cared for according to the guide-
lines of the institutional Animal Policy and Welfare Committee.
Histological analyses and immunostainings. Graft-bearing kidneys or
draining lymph nodes were harvested at indicated time points, ﬁxed in 10%
buffered formalin solution, and embedded in parafﬁn. Sections 5-m thick
from graft area were stained with hematoxylin-eosin (H-E). Immunoﬂuores-
cence staining was performed for insulin, CD3, FOXP3, and IDO. Sections
were rehydrated, and nonspeciﬁc binding was blocked. Sections were incu-
bated overnight at 4°C with appropriate primary antibodies and then washed
and incubated with relevant secondary antibodies for 45 min. Primary
antibodies include guinea pig anti-insulin antibody (1:500 dilution; Dako
Laboratories, Mississauga, Ontario, Canada), rabbit anti-CD3 antibody (1:100
dilution; abcam, Cambridge, MA), rat anti-mouse FOXP3 (1:200 dilution;
eBioscience, San Diego, CA), and rabbit anti-IDO antibody (1:1,000 dilution,
raised in rabbit; Washington Biotechnology, Baltimore, MD). Secondary
antibodies (1:2000 dilution) used were ﬂuoroisothiocyanate (FITC) goat
anti-guinea pig IgG (abcam), rhodamine goat anti-rabbit IgG (Chemicon
International, Temecula, CA), and rhodamine goat anti-rat IgG (Jackson
ImmunoResearch, West Grove, PA).
Characterization of graft-inﬁltrating cells. Composite grafts were har-
vested at indicated time points, and collagen matrices were digested using
type I collagenase (1 mg/ml; Sigma) at 37°C for 10 min. Cell suspensions were
washed with PBS and passed through a 40-m cell strainer. Cells were then
incubated for 30 min at 4°C with ﬂuorescent-conjugated antibodies (1:100
dilutions; eBioscience) speciﬁc for particular lymphocyte and antigen-present-
ing cell (APC) markers. Fluorescence dot plots were created using a BD FACS
Calibur ﬂow cytometry machine (BD Biosciences Pharmingen, Mississauga,
Ontario, Canada) and were used to determine the percentage of positive cells
labeled with the corresponding antibodies.
Quantitative PCR. Total RNA was isolated from harvested grafts at indicated
time points using an RNeasy kit (Qiagen). cDNA was synthesized using the
SuperScript ﬁrst-strand synthesis system for RT-PCR (Invitrogen, Carlsbad,
CA) according to the manufacturer’s protocol. Quantitative RT-PCR was
performed in a reaction mixture of 25 l using the Platinum SYBR Green qPCR
SuperMix-UDG with ROX (Invitrogen) PCR kit according to the manufactur-
er’s instructions. The reactions were run on a 7900 HT Fast Real time PCR
system (Applied biosystems, Foster City, CA). Human IDO-speciﬁc and mouse
cytokine and chemokine mRNAs were quantiﬁed relative to mouse glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) using primers listed in sup-
plementary Table 1 (available in an online appendix [http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1560/DC1]). The analyses were
performed with the Sequence Detection system 7900HT software (version 2.3;
Applied biosystems). All measurements were performed in duplicate. Results
are expressed as the percentage or fold increase in expression of mRNA
of interest at the indicated time point compared with day one
posttransplantation.
Serum alloantibody detection. Blood serum samples were collected from
composite graft recipients B6 mice (H-2b) at indicated time points posttrans-
plantation. Donor BALB/c mice (H-2d) thymocytes (1  10
6) were incubated
with recipient B6 mouse serum at 1:128 dilution for1ha t37°C. Thymocytes
were then washed with PBS and incubated with FITC-conjugated goat
anti-mouse IgG1 or IgG2c (1:200 dilution; AbD Serotec, Raleigh, NC) for1ha t
4°C. Binding of cells to antibody was detected from single-parameter ﬂuores-
cence histograms using a BD FACSCanto ﬂow cytometer (BD Biosciences)
after gating on viable cells. Percentage of cells shifting into an appositive
region on ﬂuorescence histogram was calculated.
Mixed lymphocyte reaction. Stimulator cells were splenocytes from islet
donor (BALB/c; H-2d) or third-party (C3H; H-2K) mouse strains, and re-
sponder cells were lymphocytes from graft-draining (renal) lymph nodes of
graft-recipient mice (B6; H-2b). Responder cells (2  10
5) were cultured with
irradiated (2000 rad) stimulator cells in 96-well round-bottom microtiter plates
(Costar, Corning, NY) for 96 h. Individual wells were pulsed with 1 Ci/well of
[
3H]-thymidine for the last 18 h. Culture plates were then harvested, and
[
3H]-thymidine incorporation was measured using a Wallac Jet 1450 Microbeta
scintillation counter (Perkin Elmer, Waltham, MA). Mean counts per minute
were determined from cultures set up in triplicate.
Statistical analysis. Data are means  SEM of three or more independent
set of experiments. Survival of islet grafts in IDO-expressing versus control
groups was compared using the Kaplan-Meier log-rank test. The statistical
differences of mean values among treated and control groups were tested with
one-way ANOVA. Post hoc comparisons were done using Student’s t test with
Bonferroni correction for multiple comparisons. P values 0.05 were consid-
ered statistically signiﬁcant.
RESULTS
Local expression of IDO prolongs islet allograft sur-
vival and function. To investigate the local immunosup-
pressive effect of IDO, three-dimensional grafts were
engineered by embedding 500 BALB/c mouse islets within
collagen matrix populated with adenoviral-transduced
IDO-expressing or control (mock vector infected or un-
treated) B6 mouse ﬁbroblasts. IDO overexpression was
validated in composite grafts (supplementary Fig. 1).
These composite grafts where then transplanted to renal
subcapsular space of streptozotocin-induced diabetic im-
mune-competent B6 mice. Another control group of mice
received only islets. Islet graft function was checked by
measuring blood glucose in graft-recipient mice. Compos-
ite IDO-expressing grafts showed a signiﬁcant prolonga-
tion of graft survival (41.2  1.64 days; P  0.001; n  10
(Table 1 and Fig. 1A). In contrast, as shown in Table 1 and
Fig. 1A, control grafts were rejected within 2 weeks after
transplantation. Mean duration of graft survival in islet-
alone group and grafts with untreated and mock virus–
treated ﬁbroblast were 12.9  0.73, 13.5  0.79, and 13.2 
0.61 days, respectively (Table 1). Mean survival duration
for mock vector–infected composite grafts was not signif-
icantly different from those of grafts with untreated ﬁbro-
TABLE 1
Composite islet graft survival in different experimental groups
n Graft survival (days posttransplantation) Mean  SE P
*
Islet plus untreated ﬁbroblasts 10 10, 11, 12 (2), 13, 14, 15 (2), 16, and 17 13.5  0.79 0.706
Islet plus mock vector ﬁbroblasts 10 10, 11, 12 (2), 13, 14 (2), 15 (2), and 16 13.2  0.61 0.908
Islet plus IDO ﬁbroblasts 10 33, 36, 38 (2), 41, 42, 43, 45 (2), and 51 41.2  1.64 0.001
Islet alone 10 10, 11 (2), 12 (3), 13, 15, 16, and 17 12.9  0.73 —
*Difference in mean survival durations compared with the islet-alone group, calculated using log-rank (Mantel-Cox) test.
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infection by itself had no effect on graft survival.
IPGTT was performed on mice that received IDO-
expressing composite grafts after 2 and 4 weeks posttrans-
plantation. As shown in Fig. 1B and C, glucose clearance
rates in mice received IDO-expressing grafts were compa-
rable with age-matched naïve animals after 2 weeks (area
under the curve 1,671.0  289.1 vs. 1,700.1  300.3 mmol 
l
1  min, respectively; P  0.05) and 4 weeks (1,870.7 
327.8 vs. 1,824.2  325.4 mmol  l
1  min; P  0.05)
posttransplantation. Normal response of islet grafts to
IPGTT demonstrated that islets in IDO-expressing com-
posite grafts are able to function normally in response to
glucose load, suggesting preservation of islet mass. These
data collectively conﬁrm that local IDO expression signif-
icantly prolongs islet allograft survival.
IDO prevents inﬁltration of lymphocytes into com-
posite grafts. A set of graft recipient mice were killed at
the end of each week posttransplantation to examine
histopathological changes in islet allografts. Composite
grafts were then recovered and stained with H-E or
subjected to immunoﬂuorescence staining for insulin,
CD3, or FOXP3. Histological studies demonstrated that
islets architecture was well preserved in the IDO-express-
ing composite grafts for up to 6 weeks (Fig. 2G–L),
whereas islets in the untreated (Fig. 2A–C)o rm o c k
vector–infected grafts (Fig. 2D–F) were almost completely
destroyed before the third week posttransplantation. Con-
trol grafts were diffusely inﬁltrated with mononuclear cells
as early as the second week posttransplantation (Fig. 2B
and E), while IDO-expressing grafts remained intact for up
to 6 weeks (Fig. 2G–K). To investigate whether a compo-
nent of immune response generated against adenovirus-
infected syngeneic ﬁbroblasts and/or human transgenic
IDO, islet-free IDO-expressing or mock vector ﬁbroblast–
populated collagen matrices were transplanted to B6 mice.
T-cell inﬁltration was not detected in IDO-expressing
grafts after 40 days posttransplant, whereas IDO transgene
was still expressed (supplementary Fig. 2).
Double staining of grafts for CD3 and insulin showed
very few insulin-producing cells and dense T-cell inﬁltra-
tion in both untreated and mock vector–infected controls
at the end of the second week posttransplantation (Fig.
3A). In contrast, islets in IDO-expressing grafts were
strongly stained for insulin and maintained their normal
architecture with minimal inﬁltration of T-cells at the same
time point (two weeks posttransplant; Fig. 3A). A remark-
able ﬁnding was that T-cells densely accumulated at the
interface between IDO-expressing graft and kidney tissue
but did not penetrate into the composite graft (IDO 2
weeks posttransplant [Figs. 2I and 3A]). However, T-cells
started to inﬁltrate IDO vector–infected grafts by the end
of the ﬁfth week posttransplant (Fig. 3A). While FOXP3
immunostaining revealed very few intragraft FOXP3
	 cells
in all experimental groups (Fig. 3B), more FOXP3
	 cells
were present in graft-draining lymph nodes of IDO-ex-
pressing recipients at week two but not week ﬁve post-
transplant (Fig. 3C).
Flow cytometry was used to determine the speciﬁc
T-cell and APC composition of the leukocyte inﬁltrates to
the grafts. As shown in Fig. 4A, CD4
	 and CD8
	 T-cells
were much more abundant in untreated (25.4 and 12.3%,
respectively) and mock vector grafts (24.7 and 10.4%)
compared with IDO-expressing grafts (3.3 and 3.4%) at 2
weeks posttransplant. Nonetheless, IDO grafts were accu-
mulated with CD4
	 and CD8
	 T-cells by week ﬁve post-
transplant (24.1 and 11.2%, respectively). Figure 4B
summarizes ﬂow cytometry data on graft-inﬁltrating cells
composition. Because IDO has been shown to regulate
APC function, the frequency of dendritic cells present in
grafts was investigated. Results showed that although the
frequency of CD11c
	 cells was less in IDO overexpressing
grafts after 2 weeks (Fig. 4A and B), the ratio of CD11c
	 to
CD3
	 cells was signiﬁcantly higher in this group (Fig. 4C),
suggesting that dendritic cells are more resistant than
T-cells to IDO effects.
Taken together, these data show that local expression of
IDO signiﬁcantly prevents inﬁltration of T-cells into islet
allografts and suggest local depletion of effctor CD4
	 and
CD8
	 T-cells as a mechanism for an antirejection function of
IDO.
Local IDO expression enhances anti-inﬂamatory Th2
type immune response and delays alloantibody pro-
duction. To further investigate the mechanism of immu-
nosuppression induced by IDO, we examined the local
cytokine/chemokine expression proﬁle and production of
donor-speciﬁc alloantibodies in composite graft recipi-
ents. Quantitative PCR showed signiﬁcantly higher proin-
ﬂammatory cytokines 
-interferon, interleukin (IL)-2, and
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FIG. 1. Islet graft survival and function after transplantation. A:
Kaplan-Meier survival curve shows prolongation of IDO-expressing
grafts survival (solid line) compared with islet alone (dash-dot line),
untreated (dashed line), and mock virus–infected (dotted line) grafts
(n  10). IPGTT after 2 weeks (B) and 4 weeks (C) posttransplanta-
tion conﬁrmed normal glucose responsiveness in graft-bearing mice
(solid line) vs. naïve mice (dashed line) (n  3). Bar charts on the right
panels show area under the IPGTT curves. Error bars indicate SEM.
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CXCL10 in untreated and mock vector grafts versus IDO-
expressing grafts two weeks posttransplantation (Fig. 5A).
Conversely, anti-inﬂammatory cytokines IL-4 and IL-10
were signiﬁcantly overexpressed in IDO grafts at the same
time point. However, cytokine/chemokine proﬁle switched
to a proinﬂammatory pattern after 5 weeks in the IDO
group (Fig. 5A). Thus, low expression of T-cell–attracting
chemokines and high levels of anti-inﬂammatory cytokines
can be considered one of the reasons for strict contain-
ment of leukocyte inﬁltration into IDO-expressing grafts.
To investigate alloantibody production, ﬂow cytometry
was used to test sera from graft recipient animals for
presence of antibodies against donor antigens. In control
groups (i.e., mice receiving untreated or mock vector
composite grafts), high levels of alloantibodies were
detectable three weeks after transplantation (Fig. 5B
and C). Higher levels of IGg2c versus IgG1 isotype was
indicative of a Th1 dominant humoral immune response
in these groups. In contrast, sera from IDO-expressing
graft recipients showed low levels of donor-speciﬁc
antibodies until the ﬁfth week posttransplant, and it
took two more weeks to reach to a level equal to that of
the control groups at week three posttransplant (Fig. 5D).
Moreover, early alloantibodies in IDO group were mainly
from IgG1 subclass, suggesting a Th2 immune response shift
in the presence of local IDO expression. These ﬁndings show
that local IDO expression promotes an anti-inﬂammatory
environment and shifts the Thl/Th2 balance toward Th2
response.
Allospeciﬁc T-cell priming is impaired in draining
lymph nodes of IDO graft recipient mice. As shown in
Fig. 3C, FOXP3
	 cells in graft-draining lymph nodes of
IDO-expressing animals were more abundant than those in
control groups at 2 weeks posttransplant. Counting the
number of FOXP3
	 cells in immunostained sections
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FIG. 2. Histology of composite islet grafts. Graft-recipient mice were killed at indicated time points posttransplantation. Composite islet grafts
were then retrieved and stained with H-E. Untreated (A–C) and mock vector infected (D–F) ﬁbroblast grafts after 1, 2, and 3 weeks
posttransplantation, respectively. G–L: IDO-expressing ﬁbroblast grafts after 1–3 and 5–7 weeks posttransplantation. Note that inﬂammation
and cellular inﬁltration into the graft started in control groups in the second week but, in the IDO group, delayed until the sixth week
posttransplantation. Scale bar: 100 m.
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	 cells in
the IDO group (9.8  0.9%; P  0.001) compared with
untreated (5.6  1.1%) and mock vector (6.2  1.2%)
groups (Fig. 6A). FOXP3
	 cell frequency, however, de-
creased in the IDO group after 5 weeks (7.0  1.1%; Fig.
7A). To investigate the impact of an increased number of
FOXP3
	 cells and other possible effects of local IDO
overexpression on T-cell priming capacity, mixed lympho-
cyte reactions were performed. The results showed a signif-
icant hyporesponsiveness of lymph node cells of IDO-
expressing group to stimulation with BALB/c (islet donor)
mouse splenocytes but not to a third-party mouse strain (Fig.
6B and C). This anergy was reverted after 5 weeks posttrans-
plant. These ﬁndings suggest that, possibly because of an
increased number of regulatory T-cells, antigen-speciﬁc in-
competence of T-cell priming occurs in draining lymph nodes
of IDO-expressing graft–recipient mice.
Duration of IDO transgene expression in composite
grafts corresponds to effectiveness of immunosup-
pression and graft survival length. In view of the
limited length of an antirejection effect of IDO in this
study, we hypothesized that a decline in the level of IDO
transgene expression can be considered a possible cause
of cessation of immunosuppression and, eventually, late
graft rejection in IDO group. We therefore tested the
length of intragraft IDO transgene expression using IDO
immunoﬂuorescence staining and quantitative PCR. Com-
posite grafts were harvested at indicated time points and
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tative PCR (qPCR). As shown in Fig. 7A, IDO protein is
expressed uniformly and widely in ﬁbroblasts throughout
the graft when tested 2 weeks after transplantation. How-
ever, after 5 weeks, only a limited number of cells in the
graft were still positive for IDO protein (Fig. 7B). The
anti-IDO antibody used in this experiment was able to
detect IDO protein from both human and mouse origins.
qPCR results showed that the IDO transgene was ex-
pressed at high levels in composite grafts containing IDO
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tation; then, the expression level started to decrease. As
presented in Fig. 7C, signiﬁcant decline in the intragraft IDO
transgene expression were observed from 100% on day one
to 47.6  13.4, 37.2  12.3, and 30.6  10.7% on days 35, 42,
and 49 posttransplantation, respectively (P  0.001; n  3).
This ﬁnding was consistent with an in vitro lasting effect of
IDO expression in ﬁbroblasts following adenoviral IDO trans-
duction (data not shown). IDO transgene mRNA was not
found in the control grafts (data not shown). Because the
IDO transgene was of human origin, by using human speciﬁc
primers we expected that intrinsic IDO expression (i.e.,
mouse IDO that expressed in grafts as a result of inﬂamma-
tion) did not interfere with IDO transgene qPCR.
These data collectively show a transient pattern for IDO
transgene expression in composite grafts following adeno-
viral gene transfer. The time course of intragraft IDO
expression closely corresponds to the duration of graft
survival and suppression of cellular and humoral alloim-
mune responses. We therefore suggest that late graft
rejection in this study was probably due to time-dependent
loss of transient IDO expression.
DISCUSSION
In the present study, we showed that local IDO expression
suppresses cellular and humoral alloimmune responses
against islets and signiﬁcantly prolongs islet allograft survival
without systemic anti-rejection treatments in diabetic im-
mune-competent mice. IDO plays a crucial role in suppres-
sion of immune responses. Several previous studies
implicated an immunomodulatory effect of IDO in different
settings including islet transplantation (28,29,37). However,
this is the ﬁrst time that IDO-expressing bystander syngeneic
ﬁbroblast–populated collagen scaffold has been used to pro-
tect islet allograft. The engineered composite graft developed
and transplanted in this study has several unique features.
First, we avoided direct transfer of IDO transgene to islets to
reduce the risk of cytotoxicity and loss of islet function.
There have been reports showing that adenoviral gene trans-
fer to islets interferes with -cell function and increases
apoptosis rate (30–32,38–39). Moreover, gene expression
after direct transduction has been observed only in the
periphery of islets and not in the islet core (40,41). Therefore,
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IDO gene transfer, we were able to induce high levels of IDO
expression as a local immunosuppressive factor while avoid-
ing any deleterious consequence of gene transfer on islet
survival and function.
Embedding islets within a three-dimensional extracellu-
lar matrix (ECM) is another advantage of this composite
graft. ECM is one of the most important constituents of the
islet microenvironment. Several studies have demon-
strated that entrapment of islets within a collagen matrix
results in satisfactory morphology, enhanced viability, and
improved insulin secretory capability in islets (42–44). As
such, embedding islets within ECM, by itself, can improve
islet graft function. Moreover, as shown in supplementary
Fig. 1, collagen matrix provides a supportive scaffold and
helps IDO-expressing ﬁbroblasts surround and protect
islets very efﬁciently in a three-dimensional structure.
Cotransplantation of ﬁbroblasts is also a beneﬁcial
aspect of this composite graft. Fibroblasts are cells of
choice to be used as bystander IDO-expressing cells
because 1) they can easily be induced to express IDO, 2)
they show low levels of DNA synthesis and become
quiescent when embedded in a collagen matrix (45), and
3) they are resistant to apoptosis in an IDO-induced
low-tryptophan environment (25,27). Fibroblasts can also
improve islet cell viability. The essential role of ﬁbroblasts
in islet physiological competence has previously been
reported, and it was shown that some ﬁbroblast-produced
factors can promote islet survival in culture (35,36). In
addition, availability of syngeneic or autologous ﬁbro-
blasts eliminates the risk of immune response against
these cells. Collectively, application of this novel compos-
ite islet graft can address a number of common obstacles
in islet allotransplantation by preventing immunological
rejection, reestablishing islet cell-ECM interaction, and
improving islet survival and function.
Findings of the present study suggest that there are
several mechanisms through which local IDO overexpres-
sion mounts its antirejection effects. These include sup-
pression of effector T-cells at the graft site, induction of a
Th2 immune response shift, generation of an anti-inﬂam-
matory cytokine proﬁle, and an increased number of
regulatory T-cells in draining lymph nodes, which results
in antigen-speciﬁc impairment of T-cell priming. As shown
in Figs. 2 and 3, T-cells accumulated at the margins of the
IDO-expressing grafts but did not invade or inﬁltrate islets.
This accords with the well-known function of IDO: gener-
ation of a low-tryptophan and high-kynurenine microenvi-
ronment within which activated T-cells are not able to
proliferate and survive. Data presented in the Fig. 1 show
that such a microenvironment protects islet grafts rejec-
tion but does not negatively affect islet function.
The transient increase in the number of FOXP3
	 cells in
our model is very similar to the pattern seen in pregnancy-
induced tolerance. It has been shown that due to local
expression of IDO in maternal-fetal interface, the number
of regulatory T-cells increases during early pregnancy,
peaking during the second trimester and followed by a
decline postpartum (46). In our model, the number of
FOXP3
	 cells increases as long as local IDO level is high,
and upon cessation of IDO overexpression in the grafts the
number of FOXP3
	 cells decreases. This is similar to Treg
downregulation after IDO levels decrease in maternal-fetal
interface postpartum.
This study for the ﬁrst time shows that local IDO
expression can inhibit production of donor speciﬁc alloan-
tibodies. The mechanism(s) underlying this phenomenon
needs further elucidation. It is well documented that
humoral response against donor-speciﬁc antigens is
clearly dependent on help provided by CD4
	 T-cells (47).
Only CD4
	 T-cells recognizing alloantigen through the
indirect pathway are able to provide cognate help to
allospeciﬁc B-cells for the development of alloantibody
(48). As such, inhibition of alloantibody production in our
study might be due to a T-cell suppressive effect of IDO
that signiﬁcantly reduces the number of donor-speciﬁc
T-cells and consequently results in insufﬁcient cognate
help to B-cells. Moreover, the Th1/Th2 shift seen in hu-
moral immune response in this study may contribute to
the IDO-induced deviation of cytokine expression proﬁle
given that IL-4 promotes IgG1 isotype switching (49),
whereas IFN-
 favors the IgG2a and IgG2c switch (50).
The ﬁnite survival of islet grafts in this study may appear
discouraging at ﬁrst glance. However, data presented here
clearly show that as long as high levels of intragraft IDO
expression was maintained, islet grafts survived and func-
tioned normally and cellular and humoral immune re-
sponses against islets were suppressed very efﬁciently.
This ﬁnding suggests that long-term protection of islet
grafts is feasible if stable IDO expression in bystander
ﬁbroblasts is achieved.
In conclusion, the present study proves the feasibility of
the development of a viable and functional IDO-expressing
composite islet graft and conﬁrms that IDO efﬁciently and
signiﬁcantly improves islet allograft survival. This promis-
ing ﬁnding proves that there is a local islet-directed
immunosuppressive effect of IDO and sets the stage for
development of a nonrejecatable islet allograft using sta-
ble IDO induction in bystander ﬁbroblasts. We are cur-
rently investigating this approach.
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